Ketorolac May Increase Hematoma Risk in Reduction Mammaplasty: A Case-control Study.

ABSTRACT:

Background

Ketorolac is a potent nonsteroidal anti-inflammatory drug that has valuable analgesic properties but also a hypothetical risk of increased bleeding due to inhibition of platelet activation. The clinical significance of this risk, however, is unclear when it is used after reduction mammaplasty. Our study objective was to therefore examine the association between ketorolac exposure and hematoma occurrence after breast reduction surgery. We hypothesized that there was no association between ketorolac exposure and hematoma occurrence in breast reduction surgery.

Methods

A case-control design was used. Data from charts of all reduction mammaplasties that developed hematomas requiring surgical evacuation (cases) at our university-based hospitals were retrieved and match

SUBMITTER: Barkho JO 

PROVIDER: S-EPMC5908486 | biostudies-literature | 2018 Mar

REPOSITORIES: biostudies-literature